PATENT CLAIM ANALYSIS

Application Number: 15895386
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["530", "387900"]

Abstract:
The present invention relates to antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias and uses thereof. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of Be-cell malignancies, including B-cell lymphomas and leukemias.

Claim (Index 51):
The method of  claim 47 , wherein the effective amount of the monoclonal antibody is administered to a subject in need thereof in combination with one or more anti-B-cell antibodies, a cytotoxin, and/or a radioisotope, thereby killing or inhibiting the growth of the B cells in a subject.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.52778
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15101658', '13612070', '14295579', '10846981', '13198263']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7008745677306117
- 35 USC 102 Novelty (BERT): 0.6385632879562897
- Combined Prediction Score: 0.6946434397531795
- Mean Citation Score: 391.229066
- Max Citation Score: 726.9009
- Similarity Product: 542.6483436895609

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test